SCHEMBL4670353

SCHEMBL4670353

Cc1ccccc1-c1ccccc1COCCOCc1ccccc1-c1ccccc1C

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FFAR1 O14842 1/20 0.46
FFAR4 Q5NUL3 1/20 0.46
HTR7 P34969 2/20 0.39
TAAR1 Q96RJ0 1/20 0.36
NPC1 O15118 2/20 0.35
RAB9A P51151 2/20 0.35
CASP3 P42574 1/20 0.35
SMN1; SMN2 Q16637 1/20 0.35
SENP8 Q96LD8 1/20 0.35
SENP7 Q9BQF6 1/20 0.35
SENP6 Q9GZR1 1/20 0.35
CHRM3 P20309 1/20 0.35
SCN8A Q9UQD0 1/20 0.35
TSHR P16473 3/20 0.35
KDM4E B2RXH2 1/20 0.35
ALDH1A1 P00352 1/20 0.35
CYP1A2 P05177 1/20 0.35
CYP3A4 P08684 1/20 0.35
CYP2D6 P10635 1/20 0.35
ALOX15 P16050 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5268171 0.92 FFAR1 (0.48) FFAR1FFAR4HTR7TAAR1NPC1
SCHEMBL30786891 0.91 FFAR1 (0.43) FFAR1FFAR4HTR7TAAR1NPC1
SCHEMBL4669318 0.89 FFAR1 (0.45) FFAR1FFAR4HTR7CHRM3SCN8A
SCHEMBL4194166 0.86 ADRB2 (0.43) FFAR1FFAR4HTR7SMN1; SMN2CHRM3
SCHEMBL7688533 0.84 DRD3 (0.44) FFAR1FFAR4SMN1; SMN2CHRM3TSHR
SCHEMBL13176996 0.82 FFAR1 (0.47) FFAR1FFAR4HTR7TAAR1NPC1
SCHEMBL9292050 0.79 FFAR1 (0.46) FFAR1FFAR4HTR7SMN1; SMN2CHRM3
SCHEMBL1314219 0.77 FFAR1 (0.43) FFAR1FFAR4HTR7TAAR1NPC1
SCHEMBL2495001 0.77 TAAR1 (0.40) FFAR1FFAR4HTR7TAAR1RAB9A
SCHEMBL2491945 0.77 FFAR1 (0.36) FFAR1FFAR4HTR7CHRM3SCN8A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1930308-A1 Pharmaceutical agents for the treatment of cerebral amyloidosis NYMOX CORPORATION (CA) 2008-06-11 EP disclosed
EP-0983222-B1 PHARMACEUTICAL AGENTS FOR THE TREATMENT OF CEREBRAL AMYLOIDOSIS NYMOX CORP (CA) 2007-11-28 EP disclosed
EP-0983222-A1 PHARMACEUTICAL AGENTS FOR THE TREATMENT OF CEREBRAL AMYLOIDOSIS NYMOX CORPORATION (CA) 2000-03-08 EP disclosed
WO-1998052898-A9 PHARMACEUTICAL AGENTS FOR THE TREATMENT OF CEREBRAL AMYLOIDOSIS NYMOX CORP (CA) 1999-04-01 WO disclosed
WO-1998052898-A1 PHARMACEUTICAL AGENTS FOR THE TREATMENT OF CEREBRAL AMYLOIDOSIS NYMOX CORPORATION (CA) 1998-11-26 WO disclosed